Loading…

Activation by Serotonin and Noradrenaline of Vasopressin and Oxytocin Expression in the Mouse Paraventricular and Supraoptic Nuclei

Noradrenaline and serotonin are known to control arginine-vasopressin (AVP) and oxytocin (OT) secretion in the systemic circulation. The aim of the current study was to investigate whether these monoamines are also able to influence AVP and OT expression in the paraventricular (PVN) and supraoptic n...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of neuroscience 2002-03, Vol.22 (5), p.1513-1522
Main Authors: Vacher, Claire-Marie, Fretier, Philippe, Creminon, Christophe, Calas, Andre, Hardin-Pouzet, Helene
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c550t-9ece1264563e2e6caeb0f76d0e08156db81487a6f1bc6b856d185b7f7a01dd073
cites
container_end_page 1522
container_issue 5
container_start_page 1513
container_title The Journal of neuroscience
container_volume 22
creator Vacher, Claire-Marie
Fretier, Philippe
Creminon, Christophe
Calas, Andre
Hardin-Pouzet, Helene
description Noradrenaline and serotonin are known to control arginine-vasopressin (AVP) and oxytocin (OT) secretion in the systemic circulation. The aim of the current study was to investigate whether these monoamines are also able to influence AVP and OT expression in the paraventricular (PVN) and supraoptic nuclei (SON). To test this hypothesis, we used the Tg8 transgenic mice KO for the monoamine oxidase-A gene, which present high levels of noradrenaline and serotonin in the brain. AVP and OT expression were evaluated at peptide and mRNA levels by immunohistochemistry, enzyme immunoassay, and in situ hybridization. Compared with wild type, the amounts of AVP, OT, AVP mRNA, and OT mRNA were increased in the PVN and SON in Tg8 mice. To distinguish the respective contributions of noradrenaline and serotonin to these modifications, we treated Tg8 mice with a synthesis inhibitor of either catecholamines [alpha-methylparatyrosine (alpha-MPT)] or serotonin [parachlorophenylalanine (pCPA)]. Administration of alpha-MPT to Tg8 mice induced a decline in the amounts of AVP, OT, and their mRNA in the PVN and SON. The pCPA treatment in Tg8 mice was also associated with a decrease in OT expression in the PVN and SON and in AVP expression in the PVN, but not in the SON. These results suggest that noradrenaline may activate AVP and OT expression in the PVN and SON. Likewise, serotonin is proposed to stimulate AVP and OT expression in the PVN and only OT expression in the SON.
doi_str_mv 10.1523/jneurosci.22-05-01513.2002
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6758852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18713611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-9ece1264563e2e6caeb0f76d0e08156db81487a6f1bc6b856d185b7f7a01dd073</originalsourceid><addsrcrecordid>eNqFkU9vEzEQxS0EoiXwFdCKA7cNY-_6TzggVVGAopIgQrlaXu9s42qzTu3dpDnzxXGaiMKJkzUzv3l640fIGwpjylnx7rbDIfho3ZixHHgOlNNizADYE3KeiEnOSqBPyTkwCbkoZXlGXsR4CwASqHxOzihVCkpFz8mvC9u7remd77Jqny0x-N53rstMV2dzH0wdsDOt6zDzTfbTRL8JGOMJWNzve29TMbs_tpNKqvoVZl_9EDH7ZoLZYtcHZ4fWhIel5bAJxm96Z7P5YFt0L8mzxrQRX53eEbn-OPsx_ZxfLT5dTi-ucss59PkELVImSi4KZCiswQoaKWpAUJSLulK0VNKIhlZWVCp1qOKVbKQBWtcgixH5cNTdDNUaa3vwZVq9CW5twl574_S_k86t9I3faiG5UunnR-TtSSD4uwFjr9cuWmxb02E6V0vKAYqJ-C9IlaSFoDSB74-gTYHGgM0fNxT0IWz9ZT67_r5YTi81Yxq4fghbH8JOy6__vudx9ZTuo42Vu1ntXEAd16ZtE071brdLglwf5Irfrca5aA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18713611</pqid></control><display><type>article</type><title>Activation by Serotonin and Noradrenaline of Vasopressin and Oxytocin Expression in the Mouse Paraventricular and Supraoptic Nuclei</title><source>PubMed Central</source><creator>Vacher, Claire-Marie ; Fretier, Philippe ; Creminon, Christophe ; Calas, Andre ; Hardin-Pouzet, Helene</creator><creatorcontrib>Vacher, Claire-Marie ; Fretier, Philippe ; Creminon, Christophe ; Calas, Andre ; Hardin-Pouzet, Helene</creatorcontrib><description>Noradrenaline and serotonin are known to control arginine-vasopressin (AVP) and oxytocin (OT) secretion in the systemic circulation. The aim of the current study was to investigate whether these monoamines are also able to influence AVP and OT expression in the paraventricular (PVN) and supraoptic nuclei (SON). To test this hypothesis, we used the Tg8 transgenic mice KO for the monoamine oxidase-A gene, which present high levels of noradrenaline and serotonin in the brain. AVP and OT expression were evaluated at peptide and mRNA levels by immunohistochemistry, enzyme immunoassay, and in situ hybridization. Compared with wild type, the amounts of AVP, OT, AVP mRNA, and OT mRNA were increased in the PVN and SON in Tg8 mice. To distinguish the respective contributions of noradrenaline and serotonin to these modifications, we treated Tg8 mice with a synthesis inhibitor of either catecholamines [alpha-methylparatyrosine (alpha-MPT)] or serotonin [parachlorophenylalanine (pCPA)]. Administration of alpha-MPT to Tg8 mice induced a decline in the amounts of AVP, OT, and their mRNA in the PVN and SON. The pCPA treatment in Tg8 mice was also associated with a decrease in OT expression in the PVN and SON and in AVP expression in the PVN, but not in the SON. These results suggest that noradrenaline may activate AVP and OT expression in the PVN and SON. Likewise, serotonin is proposed to stimulate AVP and OT expression in the PVN and only OT expression in the SON.</description><identifier>ISSN: 0270-6474</identifier><identifier>EISSN: 1529-2401</identifier><identifier>DOI: 10.1523/jneurosci.22-05-01513.2002</identifier><identifier>PMID: 11880481</identifier><language>eng</language><publisher>United States: Soc Neuroscience</publisher><subject>alpha-Methyltyrosine - pharmacology ; Animals ; Arginine Vasopressin - biosynthesis ; Arginine Vasopressin - genetics ; Enzyme Inhibitors - pharmacology ; Fenclonine - pharmacology ; Immunoenzyme Techniques ; Immunohistochemistry ; In Situ Hybridization ; Mice ; Mice, Inbred C3H ; Mice, Transgenic ; Monoamine Oxidase - deficiency ; Monoamine Oxidase - genetics ; Neurons - drug effects ; Neurons - metabolism ; Norepinephrine - antagonists &amp; inhibitors ; Norepinephrine - metabolism ; Norepinephrine - pharmacology ; Oxytocin - biosynthesis ; Oxytocin - genetics ; Paraventricular Hypothalamic Nucleus - drug effects ; Paraventricular Hypothalamic Nucleus - metabolism ; RNA, Messenger - metabolism ; Serotonin - metabolism ; Serotonin - pharmacology ; Serotonin Antagonists - pharmacology ; Supraoptic Nucleus - drug effects ; Supraoptic Nucleus - metabolism</subject><ispartof>The Journal of neuroscience, 2002-03, Vol.22 (5), p.1513-1522</ispartof><rights>Copyright © 2002 Society for Neuroscience 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-9ece1264563e2e6caeb0f76d0e08156db81487a6f1bc6b856d185b7f7a01dd073</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758852/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758852/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11880481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vacher, Claire-Marie</creatorcontrib><creatorcontrib>Fretier, Philippe</creatorcontrib><creatorcontrib>Creminon, Christophe</creatorcontrib><creatorcontrib>Calas, Andre</creatorcontrib><creatorcontrib>Hardin-Pouzet, Helene</creatorcontrib><title>Activation by Serotonin and Noradrenaline of Vasopressin and Oxytocin Expression in the Mouse Paraventricular and Supraoptic Nuclei</title><title>The Journal of neuroscience</title><addtitle>J Neurosci</addtitle><description>Noradrenaline and serotonin are known to control arginine-vasopressin (AVP) and oxytocin (OT) secretion in the systemic circulation. The aim of the current study was to investigate whether these monoamines are also able to influence AVP and OT expression in the paraventricular (PVN) and supraoptic nuclei (SON). To test this hypothesis, we used the Tg8 transgenic mice KO for the monoamine oxidase-A gene, which present high levels of noradrenaline and serotonin in the brain. AVP and OT expression were evaluated at peptide and mRNA levels by immunohistochemistry, enzyme immunoassay, and in situ hybridization. Compared with wild type, the amounts of AVP, OT, AVP mRNA, and OT mRNA were increased in the PVN and SON in Tg8 mice. To distinguish the respective contributions of noradrenaline and serotonin to these modifications, we treated Tg8 mice with a synthesis inhibitor of either catecholamines [alpha-methylparatyrosine (alpha-MPT)] or serotonin [parachlorophenylalanine (pCPA)]. Administration of alpha-MPT to Tg8 mice induced a decline in the amounts of AVP, OT, and their mRNA in the PVN and SON. The pCPA treatment in Tg8 mice was also associated with a decrease in OT expression in the PVN and SON and in AVP expression in the PVN, but not in the SON. These results suggest that noradrenaline may activate AVP and OT expression in the PVN and SON. Likewise, serotonin is proposed to stimulate AVP and OT expression in the PVN and only OT expression in the SON.</description><subject>alpha-Methyltyrosine - pharmacology</subject><subject>Animals</subject><subject>Arginine Vasopressin - biosynthesis</subject><subject>Arginine Vasopressin - genetics</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fenclonine - pharmacology</subject><subject>Immunoenzyme Techniques</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization</subject><subject>Mice</subject><subject>Mice, Inbred C3H</subject><subject>Mice, Transgenic</subject><subject>Monoamine Oxidase - deficiency</subject><subject>Monoamine Oxidase - genetics</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Norepinephrine - antagonists &amp; inhibitors</subject><subject>Norepinephrine - metabolism</subject><subject>Norepinephrine - pharmacology</subject><subject>Oxytocin - biosynthesis</subject><subject>Oxytocin - genetics</subject><subject>Paraventricular Hypothalamic Nucleus - drug effects</subject><subject>Paraventricular Hypothalamic Nucleus - metabolism</subject><subject>RNA, Messenger - metabolism</subject><subject>Serotonin - metabolism</subject><subject>Serotonin - pharmacology</subject><subject>Serotonin Antagonists - pharmacology</subject><subject>Supraoptic Nucleus - drug effects</subject><subject>Supraoptic Nucleus - metabolism</subject><issn>0270-6474</issn><issn>1529-2401</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkU9vEzEQxS0EoiXwFdCKA7cNY-_6TzggVVGAopIgQrlaXu9s42qzTu3dpDnzxXGaiMKJkzUzv3l640fIGwpjylnx7rbDIfho3ZixHHgOlNNizADYE3KeiEnOSqBPyTkwCbkoZXlGXsR4CwASqHxOzihVCkpFz8mvC9u7remd77Jqny0x-N53rstMV2dzH0wdsDOt6zDzTfbTRL8JGOMJWNzve29TMbs_tpNKqvoVZl_9EDH7ZoLZYtcHZ4fWhIel5bAJxm96Z7P5YFt0L8mzxrQRX53eEbn-OPsx_ZxfLT5dTi-ucss59PkELVImSi4KZCiswQoaKWpAUJSLulK0VNKIhlZWVCp1qOKVbKQBWtcgixH5cNTdDNUaa3vwZVq9CW5twl574_S_k86t9I3faiG5UunnR-TtSSD4uwFjr9cuWmxb02E6V0vKAYqJ-C9IlaSFoDSB74-gTYHGgM0fNxT0IWz9ZT67_r5YTi81Yxq4fghbH8JOy6__vudx9ZTuo42Vu1ntXEAd16ZtE071brdLglwf5Irfrca5aA</recordid><startdate>20020301</startdate><enddate>20020301</enddate><creator>Vacher, Claire-Marie</creator><creator>Fretier, Philippe</creator><creator>Creminon, Christophe</creator><creator>Calas, Andre</creator><creator>Hardin-Pouzet, Helene</creator><general>Soc Neuroscience</general><general>Society for Neuroscience</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20020301</creationdate><title>Activation by Serotonin and Noradrenaline of Vasopressin and Oxytocin Expression in the Mouse Paraventricular and Supraoptic Nuclei</title><author>Vacher, Claire-Marie ; Fretier, Philippe ; Creminon, Christophe ; Calas, Andre ; Hardin-Pouzet, Helene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-9ece1264563e2e6caeb0f76d0e08156db81487a6f1bc6b856d185b7f7a01dd073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>alpha-Methyltyrosine - pharmacology</topic><topic>Animals</topic><topic>Arginine Vasopressin - biosynthesis</topic><topic>Arginine Vasopressin - genetics</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fenclonine - pharmacology</topic><topic>Immunoenzyme Techniques</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization</topic><topic>Mice</topic><topic>Mice, Inbred C3H</topic><topic>Mice, Transgenic</topic><topic>Monoamine Oxidase - deficiency</topic><topic>Monoamine Oxidase - genetics</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Norepinephrine - antagonists &amp; inhibitors</topic><topic>Norepinephrine - metabolism</topic><topic>Norepinephrine - pharmacology</topic><topic>Oxytocin - biosynthesis</topic><topic>Oxytocin - genetics</topic><topic>Paraventricular Hypothalamic Nucleus - drug effects</topic><topic>Paraventricular Hypothalamic Nucleus - metabolism</topic><topic>RNA, Messenger - metabolism</topic><topic>Serotonin - metabolism</topic><topic>Serotonin - pharmacology</topic><topic>Serotonin Antagonists - pharmacology</topic><topic>Supraoptic Nucleus - drug effects</topic><topic>Supraoptic Nucleus - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vacher, Claire-Marie</creatorcontrib><creatorcontrib>Fretier, Philippe</creatorcontrib><creatorcontrib>Creminon, Christophe</creatorcontrib><creatorcontrib>Calas, Andre</creatorcontrib><creatorcontrib>Hardin-Pouzet, Helene</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vacher, Claire-Marie</au><au>Fretier, Philippe</au><au>Creminon, Christophe</au><au>Calas, Andre</au><au>Hardin-Pouzet, Helene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation by Serotonin and Noradrenaline of Vasopressin and Oxytocin Expression in the Mouse Paraventricular and Supraoptic Nuclei</atitle><jtitle>The Journal of neuroscience</jtitle><addtitle>J Neurosci</addtitle><date>2002-03-01</date><risdate>2002</risdate><volume>22</volume><issue>5</issue><spage>1513</spage><epage>1522</epage><pages>1513-1522</pages><issn>0270-6474</issn><eissn>1529-2401</eissn><abstract>Noradrenaline and serotonin are known to control arginine-vasopressin (AVP) and oxytocin (OT) secretion in the systemic circulation. The aim of the current study was to investigate whether these monoamines are also able to influence AVP and OT expression in the paraventricular (PVN) and supraoptic nuclei (SON). To test this hypothesis, we used the Tg8 transgenic mice KO for the monoamine oxidase-A gene, which present high levels of noradrenaline and serotonin in the brain. AVP and OT expression were evaluated at peptide and mRNA levels by immunohistochemistry, enzyme immunoassay, and in situ hybridization. Compared with wild type, the amounts of AVP, OT, AVP mRNA, and OT mRNA were increased in the PVN and SON in Tg8 mice. To distinguish the respective contributions of noradrenaline and serotonin to these modifications, we treated Tg8 mice with a synthesis inhibitor of either catecholamines [alpha-methylparatyrosine (alpha-MPT)] or serotonin [parachlorophenylalanine (pCPA)]. Administration of alpha-MPT to Tg8 mice induced a decline in the amounts of AVP, OT, and their mRNA in the PVN and SON. The pCPA treatment in Tg8 mice was also associated with a decrease in OT expression in the PVN and SON and in AVP expression in the PVN, but not in the SON. These results suggest that noradrenaline may activate AVP and OT expression in the PVN and SON. Likewise, serotonin is proposed to stimulate AVP and OT expression in the PVN and only OT expression in the SON.</abstract><cop>United States</cop><pub>Soc Neuroscience</pub><pmid>11880481</pmid><doi>10.1523/jneurosci.22-05-01513.2002</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0270-6474
ispartof The Journal of neuroscience, 2002-03, Vol.22 (5), p.1513-1522
issn 0270-6474
1529-2401
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6758852
source PubMed Central
subjects alpha-Methyltyrosine - pharmacology
Animals
Arginine Vasopressin - biosynthesis
Arginine Vasopressin - genetics
Enzyme Inhibitors - pharmacology
Fenclonine - pharmacology
Immunoenzyme Techniques
Immunohistochemistry
In Situ Hybridization
Mice
Mice, Inbred C3H
Mice, Transgenic
Monoamine Oxidase - deficiency
Monoamine Oxidase - genetics
Neurons - drug effects
Neurons - metabolism
Norepinephrine - antagonists & inhibitors
Norepinephrine - metabolism
Norepinephrine - pharmacology
Oxytocin - biosynthesis
Oxytocin - genetics
Paraventricular Hypothalamic Nucleus - drug effects
Paraventricular Hypothalamic Nucleus - metabolism
RNA, Messenger - metabolism
Serotonin - metabolism
Serotonin - pharmacology
Serotonin Antagonists - pharmacology
Supraoptic Nucleus - drug effects
Supraoptic Nucleus - metabolism
title Activation by Serotonin and Noradrenaline of Vasopressin and Oxytocin Expression in the Mouse Paraventricular and Supraoptic Nuclei
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A55%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20by%20Serotonin%20and%20Noradrenaline%20of%20Vasopressin%20and%20Oxytocin%20Expression%20in%20the%20Mouse%20Paraventricular%20and%20Supraoptic%20Nuclei&rft.jtitle=The%20Journal%20of%20neuroscience&rft.au=Vacher,%20Claire-Marie&rft.date=2002-03-01&rft.volume=22&rft.issue=5&rft.spage=1513&rft.epage=1522&rft.pages=1513-1522&rft.issn=0270-6474&rft.eissn=1529-2401&rft_id=info:doi/10.1523/jneurosci.22-05-01513.2002&rft_dat=%3Cproquest_pubme%3E18713611%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c550t-9ece1264563e2e6caeb0f76d0e08156db81487a6f1bc6b856d185b7f7a01dd073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18713611&rft_id=info:pmid/11880481&rfr_iscdi=true